RxDoctor Payments Data

Christopher Chuirazzi, MD

Internal Medicine · Warren, OHNPI 1215923743

Payments from drug & device makers

$1,028in general payments, 2019–2025

Across 49 payments — averaging $20.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$144
  • Pfizer$118
  • AbbVie$113
  • Novo Nordisk$92
  • Abbott$71
  • Lilly USA, LLC$69
  • plus $420 from 13 others

What the payments were for

  • Food & beverage$1,028100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,028 in reported general payments places this provider in the 70th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$137,677
Medicare patients
437
Services billed
2,105

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban233$308,680
JardianceEmpagliflozin218$280,108
XareltoRivaroxaban48$67,514
TrulicityDulaglutide50$65,014
JanuviaSitagliptin Phosphate50$55,172
OzempicSemaglutide40$50,495
EntrestoSacubitril/Valsartan26$39,338
Repatha SureclickEvolocumab29$25,357
RybelsusSemaglutide13$23,727
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$18,877
FarxigaDapagliflozin Propanediol31$18,828
MounjaroTirzepatide16$17,892
Breo ElliptaFluticasone/Vilanterol21$13,088
AtivanLorazepam12$11,425
Icosapent Ethyl13$9,320

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$118$308,680233 claims
Lilly USA, LLCTrulicity, Mounjaro, Humulin 70-30$69$86,12780 claims
Novo NordiskOzempic, Rybelsus$92$74,22253 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$56$36,90158 claims
AstraZenecaFarxiga, Symbicort$144$22,41143 claims
AbbVieSynthroid$113$3,142135 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Warren

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →